Commitments and Contingencies Facilities Lease As of June 30, 2013 , the Company leases a total of 132,176 square feet under its facility lease agreements for its U.S. corporate offices. Of the total square footage leased as of June 30, 2013 , 79,776 square feet are leased under an operating lease that expires in November 2017 , with an option to extend the lease term for an additional five years. As of June 30, 2013 , the Company also leases 52,400 square feet, of which 32,000 square feet represents additional space that the Company exercised an option to lease during six months ended June 30, 2013 , in a property adjacent to its existing corporate offices in Sunnyvale, California under an operating lease which expires in February 2023 and has an option to extend the lease term for an additional extend the term for an additional five years. In addition, during the three months ended June 30, 2013 , the Company entered into an agreement to lease approximately 7,500 square feet for its Pharmacyclics Switzerland GmbH office. The Company recognizes rental expense on the facilities on a straight-line basis over the lease term. Differences between the straight line rent expense and rent payments are classified as deferred rent liability on the balance sheet. As of June 30, 2013 , the Company's future minimum lease payments under non-cancelable operating leases are as follows: Fiscal year Operating Lease Commitments 2013 (remaining six months) $ 1,014 2014 2,266 2015 2,192 2016 2,277 2017 1,996 Thereafter 4,629 Total $ 14,374 Purchase Commitments The Company had non-cancelable purchase obligations for approximately $9,893,000 and $2,326,000 as of June 30, 2013 and December 31, 2012 , respectively. Excess Amounts under collaboration and license agreement with Janssen The Company's worldwide collaboration and license agreement with Janssen provides the Company with an annual cap of its share of development costs and pre-tax losses for each calendar year until the third profitable calendar quarter for the product, as dete